CF33-hNIS-anti-PD-L1 oncolytic virus followed by...

CF33-hNIS-anti-PD-L1 oncolytic virus followed by trastuzumab-deruxtecan in a patient with metastatic triple negative breast cancer: a case study
Hi davybabyk, WOW excellent find. What a facinating case study.
I noticed the majority of the abstract authors were from Imugene and the City of Hope.

In recent roadshows, Professor Yuman Fong mentioned he saw amazing signals from his CHECKvacc study, he also mentioned each cohort enrolled 3 patients.
IMO, data collected from CHECKvacc first 3 cohorts dosed at 10 to the power of 5 and 6 PFU, would have been vital to Imugene in successfully obtaining the FDA approval for for the design of the current MAST study.
Further patient MAST study updates to confirm the future efficacy of our CF33 oncolytic virus.

Interesting observation under the abstract "Discussion and conclusion"
"In view of the patient’s complex treatment history and prior exposure to immunotherapy including pembrolizumab and p53MVA, one may speculate that these agents may have impacted the host’s immune composition to subsequent response to CHECKvacc and T-DXd".
This answers my previous question to Nick Ede regarding the MAST combination arms using pembrolizumab.

Regards.